- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Initial phase II results of Arzerra in DLBCL released
Results have been announced from a phase II study of Arzerra (ofatumamab) in the treatment of diffuse large B-cell lymphoma (DLBCL). 81 patients were involved in the single-arm study, the majority of them heavily pre-treated by rituximab or a stem cell transplant.
The study's primary endpoint was overall response rate (ORR), which was observed to be just 11% after a median of 6,9 months. These kinds of results will make it difficult for the manufacturer to get it approved for DLBCL.
HEMATOLOGICAL CANCER TYPE(S)
Diffuse large B-cell lymphoma (DLBCL)
WHERE WAS THIS RESEARCH PUBLISHED?
The data has not yet been published.